Treatment of Acromegaly with the Growth Hormone–Receptor Antagonist Pegvisomant

Peter Trainer(University of Manchester), John A. Scarlett(International Drug Development), A.J. van der Lely(Rotterdam University of Applied Sciences), D. Roderick Rose, Suzanne Hackett, Craig Parkinson, Vivien Herman-Bonert(Cedars-Sinai Medical Center), Eleni V. Dimaraki(University of Michigan), Jeffrey S. Powell, Michael O. Thorner(Ames National Laboratory), Christian J. Strasburger(Humboldt-Universität zu Berlin), Paul M. Stewart(University of Leeds), Gudmundur Johannsson(Sahlgrenska University Hospital), Martin Bidlingmaier(LMU Klinikum), Lawrence S. Phillips(Emory University), Kenneth Zib, David L. Kleinberg(New York University), Ariel L. Barkan(University of Michigan), William F. Bennett, Robert J. Davis(University of Verona), David M. Cook, Laurence Katznelson(Stanford University), Stavros Stavrou, William M Drake(St Bartholomew's Hospital), Bengt‐Åke Bengtsson(Sahlgrenska University Hospital), Mary Lee Vance(University of Virginia), Michael C. Sheppard(University of Virginia), G. M. Besser(St Bartholomew's Hospital), Keith Friend(South Australia Pathology), Anne Klibanski(Mass General Brigham), David R. Clemmons(University of North Carolina at Chapel Hill), Mario Maldonado, Pamela U. Freda(Columbia University)
New England Journal of Medicine
April 20, 2000
Cited by 874


Related Papers